Nuvilex Inc. (NASDAQ:PMCB) Short Interest Down 90.1% in December

Nuvilex Inc. (NASDAQ:PMCB) was the target of a large drop in short interest in December. As of December 31st, there was short interest totaling 62,893 shares, a drop of 90.1% from the December 15th total of 635,629 shares. Based on an average daily trading volume, of 447,653 shares, the short-interest ratio is currently 0.1 days. Currently, 0.7% of the shares of the stock are short sold. Currently, 0.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 447,653 shares, the short-interest ratio is currently 0.1 days.

Nuvilex Stock Performance

Nuvilex stock traded up $0.02 during mid-day trading on Monday, hitting $0.90. The company’s stock had a trading volume of 299,230 shares, compared to its average volume of 433,066. Nuvilex has a one year low of $0.63 and a one year high of $1.90. The stock has a market cap of $9.10 million, a PE ratio of -0.65 and a beta of 0.04. The company has a 50 day moving average of $0.84 and a 200-day moving average of $0.94.

Nuvilex (NASDAQ:PMCB) last issued its earnings results on Thursday, December 18th. The company reported ($0.32) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Nuvilex in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Insider Buying and Selling at Nuvilex

In other Nuvilex news, CEO Joshua Silverman bought 40,000 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were purchased at an average cost of $0.83 per share, for a total transaction of $33,200.00. Following the transaction, the chief executive officer owned 416,250 shares of the company’s stock, valued at $345,487.50. This represents a 10.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have bought 110,000 shares of company stock valued at $89,000. Insiders own 10.33% of the company’s stock.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.